12:00 AM
Nov 17, 2014
 |  BC Week In Review  |  Clinical News  |  Regulatory

AMY-101 regulatory update

FDA granted Orphan Drug designation to AMY-101 to treat paroxysmal nocturnal hemoglobinuria (PNH). In 2015, the company plans to start clinical testing...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >